Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
St. Jude Children’s Research Hospital study lays the foundation for more effective treatment of childhood leukemia and a wide range of other disorders using small molecules to reverse glucocorticoid resistance. (William E. Evans, PharmD)
Research led by St. Jude Children’s Research Hospital investigators could help reduce side effects associated with the anti-cancer drug vincristine, which is widely used to treat cancer in children and adults. (William E. Evans, PharmD)
Dr. William E. Evans will retire from executive post in July 2014.
The Donald Pinkel Endowed Chair of Pediatric Cancer Treatment honors first director of St. Jude and is among the largest endowed chairs in the nation.
Scientists at St. Jude Children's Research Hospital are mining the genetic code to better match patients and medications now and in the future.
Pediatric Cancer Genome Project scientists begin to uncover treasures.
The hospital’s director and CEO reflects on how the dream of one man transformed the world.
William E. Evans, Pharm.D., is the recipient of the Remington Honor Medal, the pharmacy profession’s highest recognition
For many years, St. Jude researchers have been investigating the connection between genetics and pediatric cancer. Those approaches continue to have dramatic implications for clinical care.
Scientists working on the Pediatric Cancer Genome Project develop a powerful new tool to pinpoint the structural variations that give rise to childhood cancers.
St. Jude Children’s Research Hospital scientists tie low levels of a key DNA repair protein to loss of regulatory genes in a study that offers new clues about why acute lymphoblastic leukemia sometimes returns.
St. Jude Children’s Research Hospital has been listed among the top 10 “Best Places to Work in Academia” by The Scientist magazine—this year’s seventh place ranking is the fourth straight year the institution has placed in the top 10.
Childhood acute lymphoblastic leukemia (ALL) can be successfully treated using a carefully personalized chemotherapy regimen without cranial radiation, investigators at St. Jude Children's Research Hospital have found. Such radiation of the brain was once a standard ALL treatment to prevent recurrence of the leukemia in the central nervous system (CNS).
Scientists at St. Jude Children’s Research Hospital who represent the interdisciplinary team studying acute lymphoblastic leukemia (ALL) have been recognized by the American Association for Cancer Research (AACR) with the AACR Team Science Award.
New report from St. Jude suggests that use of gene-based diagnosis and treatment, more effective use of existing drugs and adoption of emerging strategies will continue to boost ALL cure rate.
New finding offers clinicians a more exacting way to predict whether a child with acute lymphoblastic leukemia will respond well or poorly to certain anti-cancer drugs.
The discovery of a specific pattern of gene expression is giving researchers important new insights into why standard therapies fail to cure some children with acute lymphoblastic leukemia (ALL).
The discovery of a specific pattern of gene expression linked to multiple-drug resistance of leukemic cells is giving researchers crucial information into why standard therapies fail to cure some children with acute lymphoblastic leukemia (ALL).
Improved risk classification for patients with acute lymphoblastic leukemia, more intensive chemotherapy for high risk patients and the use of a drug called dexamethasone, could one day permit physicians to omit irradiation as part of routine treatment.
Former St. Jude Director Arthur W. Nienhuis, M.D., and George Simon, chair of the St. Jude Board of Governors, recently announced that William E. Evans, Pharm.D., assumed the position of St. Jude Director and CEO. Nov. 1, 2004.
A relatively small number of genes are linked to either resistance or sensitivity to four major cancer drugs used to treat acute lymphoblastic leukemia (ALL), suggesting that these genes are key to treatment outcome.
Bill Evans' work has been compared to that of an FBI profiler. His adversary, however, is far more elusive than any illicit suspect because Evans is leading a team of scientists at St. Jude in developing genetic profiles of leukemia.
Pharmacogenomics, is a cutting-edge technology for studying how populations of specific genes control an individual's response to drug therapy.
When it comes to ALL treatment, survival rates for all children soar at St. Jude. A St. Jude team found that with equal access to effective therapy, both African-American and white patients could expect high cure rates.
Survivors of childhood acute lymphoblastic leukemia (ALL) who have not received radiation treatment as part of their therapy have virtually the same long-term life experiences as the general population.
Investigators at St. Jude Children's Research Hospital have discovered numerous genes that alter their level of activity in characteristic patterns in response to specific chemotherapy treatments.
Arthur Nienhuis, M.D., and William Evans, Pharm.D., of St. Jude Children's Research Hospital have been elected to the Institute of Medicine, a prestigious branch of the National Academy of Sciences.